Total Payments
$30,280
2024 Payments
$9,623
Companies
26
Transactions
86
Medicare Patients
2,861
Medicare Billing
$13.3M
Payment Breakdown by Category
Consulting$18,025 (59.5%)
Food & Beverage$4,178 (13.8%)
Travel$3,332 (11.0%)
Research$3,153 (10.4%)
Other$1,500 (5.0%)
Education$92.66 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,025 | 6 | 59.5% |
| Food and Beverage | $4,178 | 61 | 13.8% |
| Travel and Lodging | $3,332 | 10 | 11.0% |
| Unspecified | $3,153 | 3 | 10.4% |
| Honoraria | $1,500 | 1 | 5.0% |
| Education | $92.66 | 5 | 0.3% |
Payments by Type
General
$27,127
83 transactions
Research
$3,153
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sarepta Therapeutics, Inc. | $8,319 | 14 | $0 (2018) |
| Amicus Therapeutics, Inc. | $7,026 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $2,959 | 5 | $0 (2024) |
| UCB, Inc. | $2,720 | 1 | $0 (2022) |
| ARGENX US, INC. | $2,074 | 2 | $0 (2024) |
| CSL Behring | $1,995 | 8 | $0 (2023) |
| CATALYST PHARMACEUTICALS, INC. | $1,868 | 8 | $0 (2024) |
| Orion Corporation | $1,221 | 2 | $0 (2018) |
| Biogen, Inc. | $534.06 | 5 | $0 (2021) |
| Amgen Inc. | $324.68 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,623 | 12 | Amicus Therapeutics, Inc. ($7,026) |
| 2023 | $569.69 | 6 | CSL Behring ($433.33) |
| 2022 | $2,967 | 10 | UCB, Inc. ($2,720) |
| 2021 | $1,756 | 4 | CATALYST PHARMACEUTICALS, INC. ($1,517) |
| 2020 | $2,779 | 6 | Alexion Pharmaceuticals, Inc. ($2,550) |
| 2019 | $2,171 | 21 | CSL Behring ($1,562) |
| 2018 | $6,472 | 10 | Sarepta Therapeutics, Inc. ($5,047) |
| 2017 | $3,942 | 17 | Sarepta Therapeutics, Inc. ($3,272) |
All Payment Transactions
86 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 10/16/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $46.36 | General |
| Category: IMMUNOLOGY | ||||||
| 09/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $98.85 | General |
| Category: Neurology | ||||||
| 06/03/2024 | CATALYST PHARMACEUTICALS, INC. | — | Food and Beverage | Cash or cash equivalent | $160.75 | General |
| 06/03/2024 | CATALYST PHARMACEUTICALS, INC. | FIRDAPSE (Drug), AGAMREE | Food and Beverage | Cash or cash equivalent | $118.28 | General |
| Category: NEUROLOGY | ||||||
| 06/03/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug), FIRDAPSE | Food and Beverage | Cash or cash equivalent | $17.98 | General |
| Category: NEUROLOGY | ||||||
| 05/31/2024 | EDW Pharma, Inc. | Tiglutik (Drug) | Food and Beverage | In-kind items and services | $40.08 | General |
| Category: Neurology | ||||||
| 02/27/2024 | Amicus Therapeutics, Inc. | Pombiliti (Drug), Opfolda | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: Pompe Disease | ||||||
| 02/23/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $1,975.00 | General |
| Category: Immunology | ||||||
| 02/21/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $113.94 | General |
| Category: Rare Disease | ||||||
| 01/16/2024 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: POMPE DISEASE | ||||||
| 01/02/2024 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: POMPE DISEASE | ||||||
| 11/03/2023 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: NEUROLOGY | ||||||
| 05/23/2023 | CSL Behring | Hizentra (Biological) | — | In-kind items and services | $320.43 | Research |
| Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) • Category: Immunology | ||||||
| 05/15/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $31.60 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2023 | CSL Behring | Hizentra (Biological) | — | In-kind items and services | $112.90 | Research |
| Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) • Category: Immunology | ||||||
| 02/24/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: NEUROSCIENCE | ||||||
| 02/02/2023 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $66.38 | General |
| Category: Rare Disease | ||||||
| 10/18/2022 | Ultragenyx Pharmaceutical Inc. | — | Education | In-kind items and services | $30.00 | General |
| 10/11/2022 | UCB, Inc. | — | — | Cash or cash equivalent | $2,720.00 | Research |
| Study: Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized | ||||||
| 09/22/2022 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $11.04 | General |
| Category: IMMUNOLOGY | ||||||
| 07/27/2022 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $4.79 | General |
| Category: IMMUNOLOGY | ||||||
| 07/01/2022 | Sunovion Pharmaceuticals Inc. | KYNMOBI (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: CNS | ||||||
| 05/25/2022 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $119.26 | General |
| Category: IMMUNOLOGY | ||||||
| 05/24/2022 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), Radicava ORS | Food and Beverage | In-kind items and services | $44.73 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized | UCB, Inc. | $2,720 | 1 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | CSL Behring | $433.33 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 616 | 68,169 | $10.2M | $3.5M |
| 2022 | 14 | 764 | 85,638 | $11.3M | $3.8M |
| 2021 | 12 | 800 | 86,040 | $8.6M | $3.1M |
| 2020 | 10 | 681 | 87,620 | $8.7M | $2.9M |
Total Patients
2,861
Total Services
327,467
Medicare Billing
$13.3M
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2023 | 28 | 44,440 | $7.1M | $2.5M | 34.8% |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 24 | 15,500 | $1.7M | $579,786 | 34.0% |
| J1576 | Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 16 | 5,100 | $918,000 | $262,711 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 252 | 548 | $134,952 | $48,932 | 36.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 37 | 571 | $105,635 | $27,406 | 25.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 36 | 1,441 | $79,255 | $22,222 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 75 | $23,820 | $10,228 | 42.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 79 | 79 | $28,280 | $10,034 | 35.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 57 | 99 | $21,357 | $7,555 | 35.4% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 33 | 33 | $18,150 | $5,508 | 30.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 11 | 126 | $3,780 | $535.78 | 14.2% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 13 | 157 | $3,140 | $78.91 | 2.5% |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2022 | 35 | 39,420 | $6.3M | $2.2M | 34.6% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 33 | 25,960 | $2.9M | $955,931 | 33.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 28 | 16,600 | $1.6M | $533,115 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 278 | 579 | $113,936 | $51,970 | 45.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 47 | 734 | $135,790 | $37,263 | 27.4% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 44 | 1,671 | $91,905 | $26,318 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 107 | 107 | $33,170 | $12,995 | 39.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 69 | 118 | $25,456 | $9,434 | 37.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 67 | $17,843 | $9,077 | 50.9% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 34 | 34 | $18,700 | $5,512 | 29.5% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 15 | 15 | $6,825 | $2,149 | 31.5% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 12 | 12 | $4,140 | $1,314 | 31.8% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 15 | 156 | $4,680 | $688.27 | 14.7% |
About Dr. Kumaraswamy Sivakumar, M.D
Dr. Kumaraswamy Sivakumar, M.D is a Specialist healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821035254.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kumaraswamy Sivakumar, M.D has received a total of $30,280 in payments from pharmaceutical and medical device companies, with $9,623 received in 2024. These payments were reported across 86 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($18,025).
As a Medicare-enrolled provider, Sivakumar has provided services to 2,861 Medicare beneficiaries, totaling 327,467 services with total Medicare billing of $13.3M. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Neurology, Clinical Neurophysiology
- Location Phoenix, AZ
- Active Since 06/02/2006
- Last Updated 08/08/2019
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821035254
Products in Payments
- EXONDYS 51 (Drug) $8,319
- POMBILITI (Drug) $7,000
- Soliris (Drug) $2,675
- Hizentra (Biological) $1,995
- VYVGART (Drug) $1,975
- FIRDAPSE (Drug) $1,689
- TECFIDERA (Drug) $244.90
- Aimovig (Biological) $217.39
- PANZYGA (Biological) $188.73
- Gamunex-C (Biological) $144.05
- RADICAVA (Drug) $126.73
- CUVITRU (Biological) $120.82
- ULTOMIRIS (Biological) $113.94
- TYSABRI (Biological) $113.70
- VRAYLAR (Drug) $110.41
- OCREVUS (Biological) $105.08
- SOLIRIS (Drug) $103.20
- VYVGART HYTRULO (Drug) $98.85
- INBRIJA (Drug) $94.90
- Radicava (Drug) $80.54
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Phoenix
Dr. Anthony Yeung
Specialist — Payments: $16.8M
Specialist $16.8M
Christopher Yeung, M.d, M.D
Specialist — Payments: $3.6M
Specialist $3.6M
Dr. John Mulcahy, M.d, M.D
Specialist — Payments: $1.2M
Specialist $1.2M
Eric Eross, Do, DO
Specialist — Payments: $971,598
Specialist $971,598
Dr. Richard Dolinar, M.d, M.D
Specialist — Payments: $721,885
Specialist $721,885
Dr. Jerome Grove, Md, MD
Specialist — Payments: $213,369
Specialist $213,369